+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals



Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals



Lancet (North American Edition) 348(9023): 283-291



Background: Because the benefits of zidovudine (AZT) in HIV-infected individuals are small and do not last long the Delta trial was designed to test whether combinations of zidovudine with didanosine (ddl) or zalcitabine (ddC) were more effective than AZT alone in extending survival and delaying disease progression. Methods: The trial was randomised, double blind, and international. 3207 participants were allocated to either AZT (600 mg per day) alone (1055), AZT plus ddl (400 mg per day) (1080), or AZT plus ddC (2.25 mg per day) (1072). Participants either had symptoms of HIV disease (if AIDS, with a CD4 cell count of gt 50 times 10-6/L) or a CD4 count of less than 350 times 10-6/L; 2124 had not had zidovudine before (Delta 1) and 1083 had for at least 3 months (Delta 2). Findings: Over a median follow-up of 30 months, 699 participants died, and 936 of the 2765 without AIDS at entry developed AIDS or died. In participants who had not had AZT before, both combination regimens had substantial benefits in terms of survival (regardless of disease stage at entry); a relative reduction in mortality of 42%, compared to AZT alone (95% CI 25% to 55%), for AZT plus ddl and of 32% (95% CI 22% to 47%) for AZT plus ddC. In participants who had had AZT before, the addition of ddl improved survival (p=0.05; relative reduction 23% (95% CI 0% to 41%)) but there was no direct evidence of benefit from the addition of ddC (p=0.47; relative reduction 9% (95% CI-17% to 29%)). The overall difference in survival between the treatment groups was significant (p lt 0.0001; a relative reduction in mortality, compared to AZT alone, of 33% (95% CI 20% to 44%) for AZT plus ddl and 21% (95% CI 6% to 34%) for AZT plus ddC). Benefit in terms of disease progression was seen mainly in participants not previously treated with AZT and overall. There was no unexpected toxicity from the combination treatments. Interpretation: Initiation of treatment with combinations of AZT plus ddl or ddC prolongs life and delays disease progression compared with AZT alone. The addition of ddl to participants already treated with AZT also improves survival, although the benefit appears less.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008427884

Download citation: RISBibTeXText

DOI: 10.1016/s0140-6736(96)05387-1


Related references

Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 348(9023): 283-291, 1996

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. JAMA (Journal of the American Medical Association) 279(12): 930-937, 1998

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 279(12): 930-937, 1998

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus zalcitabine is preferred to zidovudine plus didanosine. Reviews in Medical Virology 4(1): 5-8, 1994

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabine. Reviews in Medical Virology 4(1): 9-12, 1994

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Annals of Internal Medicine 124(12): 1019-1030, 1996

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Annals of Internal Medicine 125(3): 161-172, 1996

Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviraltherapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3. Revista do Instituto de Medicina Tropical de Sao Paulo 42(1): 27-36, 2000

Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee. Antiviral Therapy 2(4): 229-236, 1997

A six months follow-up randomized controlled trial of lamivudine combined with zidovudine vs lamivudine plus zidovudine plus zalcitabine or didanosine in HIV-1 infection and CD4+ cell count between 50-300/mu-L. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36: 206, 1996

The Albi Trial: A Randomized Controlled Trial Comparing Stavudine Plus Didanosine with Zidovudine Plus Lamivudine and a Regimen Alternating Both Combinations in Previously Untreated Patients Infected with Human Immunodeficiency Virus. The Journal of Infectious Diseases 180(2): 351-358, 1999

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. Journal of Infectious Diseases 180(2): 351-358, 1999

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. Aids Research and Human Retroviruses 16(14): 1337-1344, 2000

Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group. Annals of Internal Medicine 120(5): 360-368, 1994

Saquinavir + zalcitabine vs saquinavir or zalcitabine monotherapy in HIV-infected patients discontinuing or intolerant to zidovudine Results of a randomized, double blind trial. AIDS (London) 10(Suppl. 2): S17, 1996